XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
R
R

RECSilicon

News

Reuters - 2 weeks ago

Italy - Factors to watch on Nov. 11

CORRECTED-Italy - Factors to watch on Nov. 11 Corrects number in paragraph 6 to million from billion The following factors could affect Italian markets on Monday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . COMPANIES ENEL ENEI.MI Brazil's solicitor general's office said on Friday that it is suing the Italian energy group for 260 million reais ($45.12 milli
A
B
E
E
G
H
L
R
S
T
U
A
B
B
D
J
M
R
R
I
U
Reuters - 2 weeks ago

Italy's Recordati sees no impact from potential US pharma tariffs

UPDATE 1-Italy's Recordati sees no impact from potential US pharma tariffs Adds from paragraph 4 background, CFO quotes By Giancarlo Navach MILAN, Nov 7 (Reuters) - Italian drug maker Recordati RECI.MI is not concerned about potential new U.S. tariffs under president-elect Donald Trump as it expects them to have no impact on its rare diseases business, the company's chief financial officer said on Friday.
R
S
Reuters - 2 weeks ago

Italy's Recordati sees no impact from potential U.S. pharma tariffs

Italy's Recordati sees no impact from potential U.S. pharma tariffs By Giancarlo Navach MILAN, Nov 7 (Reuters) - Italian drug maker Recordati RECI.MI is not afraid of potential new U.S. tariffs under president-elect Donald Trump as it expects them to have no impact on its rare diseases business, the company's chief financial officer said on Friday.
R
Reuters - 2 weeks ago

Italian pharmaceutical firm Recordati's 9-month profit leaps 11.8%

Italian pharmaceutical firm Recordati's 9-month profit leaps 11.8% Nov 8 (Reuters) - Italian drug maker Recordati RECI.MI posted on Friday a 11.8% jump in its nine-month core profit (EBITDA) boosted by strong business momentum in both specialty and primary care and rare diseases segments. The Milan-based company January-September core profit totalled 665.7 million euros ($717.69 million), while its revenue stood at 1.74 billion euros, up 12% year-on-year.
R
Reuters - 2 weeks ago

Recordati 9M Adj. Net Profit EUR 445.4 Mln

BRIEF-Recordati 9M Adj. Net Profit EUR 445.4 Mln Nov 8 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA RECI.MI : 9M REVENUE EUR 1.74 BILLION 9M EBITDA EUR 665.7 MILLION 9M ADJUSTED NET PROFIT EUR 445.4 MILLION PROPOSES INTERIM DIVIDEND FOR 2024 OF EUR 0.60 PER SHARE CONFIRMS 2024 OUTLOOK, EXCLUDING CONTRIBUTIONS FROM ENJAYMO DEAL, EXPECT
R
Reuters - 2 weeks ago

Italy - Factors to watch on Nov.8

Italy - Factors to watch on Nov.8 The following factors could affect Italian markets on Friday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . POLITICS Italy urged the European Union on Thursday to guarantee bond issuance needed to finance defence , saying a NATO spending target of at least 2% of gross domestic product (GDP) by 2028 clashed with the EU's reva
A
B
B
D
E
L
L
M
N
R
S
U
B
F
M
P
I
U
Reuters - 1 month ago

Basler AG, Greatland Gold, Sandvik AB

EUROPE RESEARCH ROUNDUP-Basler AG, Greatland Gold, Sandvik AB Oct 22 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Basler AG, Greatland Gold and Sandvik AB, on Tuesday. HIGHLIGHTS * Autoneum Holding AG AUTON.S : UBS raises PT to CHF 170 from CHF 160 * Azelis NV AZE.BR : HSBC raises to buy from hold * Basler AG BSLG.DE : Jefferies cuts to hold from buy * Greatland Gold Plc GGPL.L : Berenberg cuts to hold from buy * Sandvik AB SAND
A
B
E
F
G
I
I
N
P
R
S
S
S
T
R
Reuters - 2 months ago

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Monte dei Paschi di Siena, Apollo Global Management, updates Coeur Mining Oct 4 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1950 GMT on Friday: ** Italy aims to sell up to around 15% of Monte dei Paschi di Siena BMPS.MI in an upcoming share placement, reducing the government's stake in the bailed-out bank to as low as 12%, two sources close to the matter told Reuters on Friday.
B
E
I
J
R
R
S
M
Reuters - 2 months ago

Recordati looks for M&A deal in rare diseases, specialty, primary care sectors

BRIEF-Recordati looks for M&A deal in rare diseases, specialty, primary care sectors Oct 4 (Reuters) - Recordati CEO Rob Koremans tells analysts: CONTINUES TO LOOK FOR A M&A DEAL, LOOKS AT RARE DISEASES, SPECIALTY AND PRIMARY CARE SECTORS Further company coverage: RECI.MI
R
Reuters - 2 months ago

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Oct 4 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Friday: ** Italian pharma group Recordati RECI.MI said it would buy from Sanofi SASY.PA the global rights to a drug used to treat cold agglutinin disease, a rare autoimmune disorder, for $825 million, sending both stocks up in early trade.
J
R
S
Reuters - 2 months ago

Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln

UPDATE 1-Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln Adds share moves, trader comment in paragraphs 3-4 Oct 4 (Reuters) - Italian pharma group Recordati RECI.MI said on Friday it would buy from Sanofi SASY.PA the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million, sending both stocks up in early trade.
R
S
Reuters - 2 months ago

Recordati rises after $825 mln global drug rights deal with Sanofi

BUZZ-Recordati rises after $825 mln global drug rights deal with Sanofi ** Shares of Recordati RECI.MI rise around 5% after the Italian pharma group said it would buy from Sanofi SASY.PA the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million ** "Very positive deal which optimises produc
R
S
Reuters - 2 months ago

Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln

Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln Oct 4 (Reuters) - Italian pharma group Recordati RECI.MI said on Friday it would buy from Sanofi SASY.PA the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million. The deal includes additional commercial milestone payments of up to $250 million and will be completed by year-end, subject to regulatory approval, the Italian company said.
R
S
Reuters - 2 months ago

Recordati Signs $825 Mln Deal With Sanofi To Buy Global Rights To Enjaymo

BRIEF-Recordati Signs $825 Mln Deal With Sanofi To Buy Global Rights To Enjaymo Oct 4 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA RECI.MI : SIGNS DEAL WITH SANOFI TO BUY GLOBAL RIGHTS OF ENJAYMO TO PAY UP-FRONT $825 MILLION, ADDITIONAL PAYMENTS CONNECTED TO COMMERCIAL RESULTS UP TO $250 MILLION CLOSING EXPECTED BY YEAR-END, SUBJECT T
R
S
Reuters - 2 months ago

Italy - Factors to watch on October 4

Italy - Factors to watch on October 4 The following factors could affect Italian markets on Friday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . ECONOMY ISTAT releases Q2 deficit/GDP ratio data (0800 GMT) and August retail sales data (1000 GMT).
C
E
M
R
R
S
U
I
M
T
I
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.